# US 8,278,272 B2 · GLP-1, exendin-4, peptide analogs and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,272 B2
- Document ID: US8278272B2
- Status: Granted
- Kind: B2
- Application number: 12/317,042
- Filed: 2008-12-18
- Published: 2009-10-08
- Granted: 2012-10-02
- Earliest claimed: 2001-07-31
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Inventors: Nigel Greig; Josephine Egan; Maire Doyle; Harold Holloway; Tracy Ann Perry
- Web page: https://patentgrep.com/patent/US8278272B2

## CPC

- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 7/12: Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P5/10)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/57563: {Vasoactive intestinal peptide [VIP]; Related peptides}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/2278: {Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)}
- A61K 38/26: Glucagons
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.

## Claims

### Claim 1

A method of treating a subject with a neurodegenerative disease or of reducing one or more symptoms of a neurodegenerative disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a polypeptide comprising GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analogue, wherein the polypeptide binds to and activates a receptor that binds GLP-1, exendin-4, or both, and wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, Huntington's disease, or amyotrophic lateral sclerosis.

### Claim 2 (depends on 1)

The method of claim 1, wherein the neurodegenerative disease is Alzheimer's disease.

### Claim 3 (depends on 1)

The method of claim 1, wherein the neurodegenerative disease is Parkinson's disease.

### Claim 4 (depends on 1)

The method of claim 1, wherein the neurodegenerative disease is Huntington's disease.

### Claim 5 (depends on 1)

The method of claim 1, wherein the neurodegenerative disease is amyotrophic lateral sclerosis.

### Claim 6 (depends on 1)

The method of claim 1, wherein the polypeptide is insulinotropic.

### Claim 7 (depends on 1)

The method of claim 1, wherein the polypeptide is longer acting than GLP-1.

### Claim 8 (depends on 1)

The method of claim 1, wherein the polypeptide has a greater binding affinity for the GLP-1 receptor than does GLP-1.

### Claim 9 (depends on 1)

The method of claim 1, wherein the polypeptide is selected from the group consisting of SEQ ID NOs: 9, 42-48, and 50-52.

### Claim 10 (depends on 1)

The method of claim 1, wherein the polypeptide comprises GLP-1 or a therapeutically effective GLP-1 analogue.

### Claim 11 (depends on 10)

The method of claim 10, wherein the polypeptide is selected from the group consisting of SEQ ID NOs: 5-6 and 8.

### Claim 12 (depends on 10)

The method of claim 10, wherein the polypeptide is insulinotropic.

### Claim 13 (depends on 10)

The method of claim 10, wherein the polypeptide is longer acting than GLP-1.

### Claim 14 (depends on 10)

The method of claim 10, wherein the polypeptide has a greater binding affinity for the GLP-1 receptor than does GLP-1.

### Claim 15 (depends on 1)

The method of claim 1, wherein the polypeptide comprises exendin-4 or a therapeutically effective exendin-4 analogue.

### Claim 16 (depends on 15)

The method of claim 15, wherein the polypeptide is selected from the group consisting of SEQ ID NOs: 10-12 and 33.

### Claim 17 (depends on 15)

The method of claim 15, wherein the polypeptide is insulinotropic.

### Claim 18 (depends on 15)

The method of claim 15, wherein the polypeptide is longer acting than GLP-1.

### Claim 19 (depends on 16)

The method of claim 16, wherein the polypeptide has a greater binding affinity for the GLP-1 receptor than does GLP-1.

### Claim 20

A method for treating a neurodegenerative disease in a human in need thereof, comprising administering a therapeutically effective amount of exendin-4 to the human to treat the neurodegenerative disease, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, Huntington's disease, or amyotrophic lateral sclerosis.

### Claim 21 (depends on 20)

The method of claim 20, wherein the neurodegenerative disease is Alzheimer's disease.

### Claim 22 (depends on 20)

The method of claim 20, wherein the neurodegenerative disease is Parkinson's disease.

### Claim 23 (depends on 20)

The method of claim 20, wherein the neurodegenerative disease is Huntington's disease.

### Claim 24 (depends on 20)

The method of claim 20, wherein the neurodegenerative disease is amyotrophic lateral sclerosis.
